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AbstrACt
Introduction Healthcare researchers designing strength-
based exercise interventions must choose an appropriate 
dose to test before evaluating its effect using a definitive/
phase-III randomised controlled trial (RCT). Compared 
with early phase testing employed by pharmaceutical 
trials, it is questionable whether exercise-based trials 
employ the same rigour for establishing tolerated 
dosage. Consequently, it is unclear if participants are 
initially prescribed optimal doses of exercise, which 
may potentially impact on study outcomes. Using trials 
of strength-based exercise interventions in adults with 
rheumatoid arthritis (RA) as an exemplar, the aims of this 
review are to (1) identify the proportion of RCTs that use 
phase I/II trials with dose escalation methodology for 
setting prescription parameters, (2) determine type and 
level of evidence used to justify prescription parameters of 
strength-based exercise interventions evaluated by RCTs, 
(3) explore consistency and applicability of the evidence 
underpinning prescription parameters in RCTs and (4) 
explore if a relationship exists between risk of bias for 
RCTs evaluating strength-based interventions and the level 
of evidence used to underpin prescription parameters.
Methods and analysis Focusing on RCT’s evaluating 
strength-based exercise interventions in adults with RA 
published after 2000, the following databases will be 
searched: Allied and Complementary Medicine Database, 
Cochrane Central Register of Controlled Trials, Cumulative 
Index to Nursing and Allied Health Literature, Excerpta 
Medica Database, Medline and Physiotherapy Evidence 
Database. For each RCT, we will identify the evidence 
used to underpin prescription parameters. Both trial and 
underpinning evidence will have key information about the 
intervention extracted using the template for intervention 
description and replication checklist. Risk of bias will be 
assessed according to Cochrane. Levels of evidence will 
be assessed against the Oxford Centre for Evidence-Based 
Medicine and relationships between RCT and underpinning 
evidence explored and described narratively. Two 
independent assessors will be involved throughout data 
selection and extraction with recourse to a third reviewer 
should agreement not be reached.
Ethics and dissemination No ethical issues are 
identified. Dissemination will be via publication.
PrOsPErO registration number CRD42018090963.
IntrOduCtIOn
Developing the interventions evaluated as 
part of a clinical trial is a critical stage of 
the research process. An integral part of 
this process focuses on determining safe 
and effective prescription of dose, yet the 
approaches used by healthcare researchers 
differ depending on the type of intervention 
being tested. Those evaluating investigational 
medicinal products commonly use early phase 
clinical trials (eg, phase I/II), employing 
different dose escalation designs1 2 as an 
essential step to safeguard participants and 
optimise potential for efficacy.3 4 Conversely, 
researchers evaluating complex rehabilita-
tion interventions involving exercise seldom 
take this approach. Instead, many follow the 
Medical Research Council (MRC) framework 
for developing and evaluating randomised 
strengths and limitations of this study
 ► This review presents a novel approach to inves-
tigating the dose prescriptions used for exercise 
interventions evaluated in randomised controlled 
trials (RCTs) using trials in rheumatoid arthritis as 
an example.
 ► It will identify how many RCTs evaluating strength-
based exercise interventions in rheumatoid arthritis 
report using early phase trials to set prescription 
parameters.
 ► This review will examine consistency and applicabil-
ity of the evidence used by healthcare researchers 
to underpin the prescription parameters.
 ► A limitation of the review is that we must rely on 
the description of interventions provided by the au-
thors, so findings will be reliant on the quality of this 
reporting.
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controlled trials (RCTs) for complex interventions used 
to improve health.5–7 This framework has parallels with 
the phases used for evaluating investigational medicinal 
products: (1) preclinical (theory), (2) phase I (model-
ling), (3) phase II (exploratory trial), (4) phase III 
(definitive RCT) and (5) phase IV (long-term implemen-
tation). Phases 1–3 specifically relate to developing the 
intervention and include setting prescription parameters 
(ie, recommended dose and/or schedule).
Eighteen years have passed since the MRC produced 
the first version of its framework. In both the original 
(2000) and updated version (2006), the MRC recom-
mends piloting and exploratory clinical testing for 
addressing key uncertainties (eg, dose parameters). Yet, 
in a provisional scoping search of the literature, phase 
I/II trials appear to be poorly adopted by healthcare 
researchers evaluating exercise-based interventions. 
However, available studies illustrate that formal investi-
gation of tolerance to an exercise-based intervention in 
people with health conditions can help to address these 
uncertainties prior to undertaking a larger, more costly 
trial. These studies challenge previous research that did 
not use a dose escalation design.8–10 For example, we 
located two trials which used 3+3 dose escalation meth-
odology to determine the maximum tolerated dose of 
exercise interventions. The first involved a multimodal 
exercise programme (endurance training, progressive 
resistance training and task-related practice) and its effect 
on walking endurance, balance and mobility in commu-
nity dwelling stroke survivors with diminished mobility.11 
The results indicated that almost double the amount of 
exercise could be tolerated compared with that used in 
previous studies in similar cohorts. The second aimed to 
determine the maximum tolerated dose of walking exer-
cise in people with severe osteoarthritis of the knee.12 The 
maximum tolerated dose of walking was 80 min less per 
week than the 150 min of physical activity recommended 
by WHO for healthy adults aged 18–64.10
In the absence of such information acquired from early 
phase testing, researchers must rely on expert opinion 
and/or consensus or draw from the available evidence 
(eg, previous trials, cohort studies, exercise guidelines 
for non-clinical populations, etc.) to develop the inter-
ventions they wish to evaluate. We hypothesise that the 
potential impact of this approach is that the exercise inter-
ventions being tested in clinical trials are not optimised 
for specific populations prior to testing. This hypothesis 
has not been explored previously. Therefore, the aim of 
this review is to better understand about how healthcare 
researchers develop exercise interventions and set dose 
parameters for testing in an RCT.
A large number of exercise interventions have been 
evaluated across many musculoskeletal conditions and 
to include all trials of exercise interventions would be 
beyond the scale of this review. Therefore, we have chosen 
to focus on trials of strength-based exercise interventions 
evaluated in patients with rheumatoid arthritis (RA) 
for this review. RA is a painful and debilitating systemic 
inflammatory chronic condition13 that affects approxi-
mately 1% of the population in the UK.14 The economic 
impact in relation to cost is substantial.15 We have chosen 
strength-based exercise for two reasons: (1) it has been 
recommended in the management of RA16 17 and (2) the 
optimal dose–response relationships regarding strength 
training variables (eg, volume, intensity, frequency, etc) 




1. To determine what proportion of published RCTs eval-
uating strength-based interventions in RA report using 
stand-alone phase I/II trials for setting prescription pa-
rameters. This includes the authors of the RCTs con-
ducting their own study or specifically citing evidence 
from such a study.
secondary objectives
1. To determine what type and level of evidence is used 
to underpin prescription parameters of strength-based 
exercise interventions in RA evaluated by RCTs.
2. Explore the consistency and applicability of the evi-
dence used to underpin between prescription parame-
ters and study populations in RCTs evaluating strength-
based exercise interventions in RA.
3. To explore if a relationship exists between risk of bias 
for RCTs evaluating strength-based interventions in RA 
and the level of evidence for underpinning prescrip-
tion parameters.
MEthOds And AnAlysIs
Overview of methodological approach
This protocol was drafted using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis Proto-
cols checklist.20 We will identify RCTs (these will be called 
the primary evidence sources) evaluating strength-based 
exercise interventions in adults with RA. During data 
extraction of the primary evidence source, we will identify 
the citation/s (we will call these the secondary evidence 
sources) used to underpin the prescribed intervention, 
specifically the prescription parameters. We will then 
obtain the secondary evidence source/s and perform 
further data extraction. Should the secondary evidence 
source be a literature review, clinical guideline or pilot 
study, we will identify where possible, the citation/s 
(these will be called the tertiary evidence sources) most 
relevant to underpinning the prescription parameters for 
the intervention from the primary evidence source.
Criteria for considering studies for this review
We will include all published RCTs where a main compo-
nent of the intervention being evaluated will be land-based 
strengthening exercise for adults with RA. Strengthening 
exercises may involve the individual using equipment 
(e.g. free weights/machines), or their own bodyweight 
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to provide resistance against gravity (e.g. sit-to-stand exer-
cise). The intervention may be unsupervised, supervised 
or both and carried out individually, or in a group. The 
strength-based intervention may be multifactorial (eg, 
used in conjunction with cointerventions like education) 
or multicomponent (e.g. used with other forms of exer-
cise like flexibility exercise).
types of participant
Studies will be eligible if they only include adults (men 
and women over 18 years of age) with a diagnosis of RA. 
We will not limit inclusion to studies using classification 
criteria such as the 2010 American College of Rheuma-
tology/European League Against Rheumatism Classi-
fication Criteria for Rheumatoid Arthritis21 to ensure 
we identify as many RCTs using strength-based exercise 
interventions to treat RA as possible.
stage 1: search methods for identification of studies
Electronic searches
We will search the following databases: Allied and Comple-
mentary Medicine Database (AMED), Cochrane Central 
Register of Controlled Trials (CENTRAL), Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), 
Excerpta Medica Database (Embase), Ovid Medline and 
Physiotherapy Evidence Database (PEDro) using tailored 
search strategies. Box 1 presents the search strategy for 
Medline. We will limit our search to start from April 2000. 
This is when the MRC published their original framework 
for developing and evaluating RCTs for complex inter-
ventions used to improve health. We present the flow 
diagram of the study selection process (figure 1).
Searching other resources
In addition to the above, we will check reference lists of 
retrieved studies for relevant articles.
stage 2: selection of studies (title and abstract screening)
Duplicate records will be removed using the web-based 
software platform Covidence22 commonly used by 
Cochrane authors for screening and data extraction. 
Two review authors (GB, VG) will then use this platform 
to independently screen the title and abstract of each 
remaining record to determine which studies should be 
assessed further. We will transfer a record for full-text 
screening should the review authors disagree.
stage 3: selection of studies (full-text screening)
Full text will be uploaded to Covidence where review 
authors (GB, VG) will investigate all potentially rele-
vant articles. Where full text is not available online, we 
will contact the corresponding author of the included 
study to obtain a copy. Disagreement between the review 
authors (GB, VG) about whether to include or exclude a 
record will be resolved by discussion. If consensus cannot 
be reached, we will consult a third reviewer (NO) for arbi-
tration will be implemented. If resolving disagreement is 
not possible, the article will be added to those ‘awaiting 
assessment’ and we will contact the study authors for 
clarification about any points of disagreement raised by 
the review authors (GB, VG, NO) so that a final decision 
can be made.
stage 4: data extraction (primary evidence source)
A data extraction form will be developed and piloted 
using a representative sample of included studies in 
order to identify any missing items or unclear coding 
instructions. Once the data extraction form is finalised, 
two review authors will independently extract data from 
box 1 Medline search strategy
search terms
1. Arthritis, Rheumatoid/
2. (RA or rheumatoid).ti,ab.





8. Exercise Movement Techniques/
9. Physical Therapy Modalities/
10. Physical Fitness/
11. Physical Endurance/
12. (exercis$ adj1 (home or programme$ or program$ or therap$ or 
technique$ or train$ or treatment$ or intervention$ or supervised)).
ti,ab,kw.
13. ((therapeutic or land or intensi$ or dynamic or isometric or isotonic 
or isokinetic) adj3 (exercis$ or train$)).ti,ab,kw.
14. (physical adj1 (activ$ or education$ or fitness or train$ or therap$ 
or treatment$ or intervention$)).ti,ab,kw.
15. (physio or physiotherap$).ti,ab,kw.
16. (cycle or cycling or bicycle or walk$).ti,ab,kw.
17. (physical adj1 condition$ adj1 (exercis$ or train$ or programme$ 
or program$)).ti,ab,kw.
18. ((muscle or grip$) adj2 (programme$ or program$ or therap$ or 
technique$ or train$ or treatment$ or intervention$ or exercis$)).
ti,ab,kw.
19. ((hand$ or wrist$ or shoulder$ or knee$ or ankle$ or joint$ or el-
bow$ or hip or cervical or lumbar or trunk) adj1 (strength$ or exer-
cis$ or therap$)).ti,ab,kw.
20. Resistance Training/
21. ((resistance or strength$ or weight or endurance) adj1 (pro-
gramme$ or program$ or therap$ or technique$ or train$ or treat-
ment$ or intervention$ or exercis$)).ti,ab,kw.
22. or/5–21
23. 4 and 22
24. randomized controlled trial.pt.








33. 23 and 32
34. exp animals/not humans.sh.
35. 33 not 34
36. limit 35 to yr =‘2000–2018’
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the included primary evidence sources. Disagreement 
will be resolved by discussion. If consensus cannot be 
achieved, a third review author (NO) will act as arbi-
trator. The following data will be extracted: 1) trial 
information (trial design, study location (country), 
setting, sample size, inclusion and exclusion criteria), 
(2) participant information (how sample was recruited, 
study inclusion and exclusion criteria, total number of 
participants randomised, total number of participants in 
intervention and control arms, total number of partici-
pants lost to follow-up, participant age, participant sex, 
participant ethnicity), (3) intervention information using 
the template for intervention description and replica-
tion (TIDieR) checklist and guide.23 Items 2 and 8 from 
the TIDieR checklist will assist with identifying whether 
early phase testing (phase I and II) was undertaken. We 
will define a phase I–II trial as a stand-alone study that 
was used by the healthcare researchers of the primary 
evidence source to learn more about what the best dose 
to use was and its potential for side effects. Pilot studies 
conducted within the RCT, whereby the study participants 
are included in the final analysis, will not be defined as 
an early phase I–II trial. Where appropriate, we will use 
intervention and/or protocol publications linked to the 
primary evidence source to assist with extracting informa-
tion about the intervention, (4) description of outcomes 
measures used and brief summary of findings and (5) full 
citation/s (if used) by the trial authors to underpin the 
strength-based prescription parameters for the interven-
tion (the secondary evidence source/s). Where appro-
priate, we will use intervention and protocol publications 
linked to the primary evidence source to assist with identi-
fying the secondary evidence source/s. We anticipate that 
some underpinning secondary evidence sources may be a 
literature review, clinical guideline or pilot study. Should 
this be the case, we will also identify the tertiary evidence 
source/s that seem most relevant to underpinning the 
prescription parameters.
stage 5: data extraction (secondary/tertiary evidence source)
We will obtain full text of the secondary and tertiary 
evidence source/s identified at stage 4. Where full text 
is not available online, we will contact the corresponding 
author to obtain a copy. We will extract data using the 
extraction form used in stage 4. We will indicate when 
the secondary/tertiary evidence source/s are not primary 
research.
stage 6: analysis
For each primary evidence source, we will outline in table 
format the information collected at stage 4. We will then 
use the question: ‘Does this intervention help?’ taken from 
the Oxford Centre for Evidence-Based Medicine—Levels 
of Evidence24–26 to grade the secondary and/or tertiary 
evidence source/s. Using the information collected with 
the TIDieR checklist and guide, we will narratively explore 
and identify areas of homogeneity and heterogeneity 
between primary evidence source and the underpinning 
secondary and/or tertiary evidence sources. Inconsisten-
cies in study populations (eg, gender, age, ethnicity, etc), 
intervention prescription parameters (eg, type of exer-
cise, volume, load, intensity, duration, frequency, etc) 
and study outcomes (eg, primary and secondary) used 
will be reported using a simple ‘Yes=Consistent’, ‘No=In-
consistent’ or ‘Unclear=Not reported’ coding strategy. 
We will also explore narratively the relationship between 
risk of bias for the primary evidence source and the level 
of evidence established for the underpinning evidence 
sources linked to the prescription parameters.
risk of bias assessment
For the primary sources, we will assess the risk of bias 
using the six key domains of the Cochrane risk of bias 
tool: (1) random sequence generation, (2) allocation 
concealment, (3) blinding of participants and personnel, 
(4) blinding of outcome assessors, (5) incomplete 
outcome data and (6) selective outcome reporting.27 
Two review authors will independently assess risk of bias 
of each included RCT. Disagreement will be resolved by 
discussion, or recourse to a third reviewer (NO). Where 
appropriate, we will assess risk of bias of the underpin-
ning evidence (secondary and tertiary evidence sources). 
Where the study is a non-randomised controlled cohort 
design, we will use Cochrane’s Risk Of Bias In Non-Ran-
domized Studies of Interventions tool.28
Patient and public involvement
Patients and the public were not involved in the design of 
this systematic review.
dIsCussIOn
We present a protocol for a novel systematic literature 
review to expand our understanding of how healthcare 
Figure 1 Flow diagram of the study selection process.
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researchers develop exercise interventions and set dose 
parameters for testing in RCTs. This is especially important 
as the published descriptions of interventions are 
frequently incomplete.29 The use of a narrative approach 
to analyse the extracted data is essentially exploratory in 
nature. However, we contend that given the likely mixed 
and unpredictable nature of the evidence reviewed, such 
an approach is most appropriate.
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